• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Andaris agent enters renal study

Article

Ultrasound contrast developer Andaris is exploring radiological applications for its Quantison agent. The Nottingham, U.K.-based company has begun a phase II clinical trial to examine the efficiency of the intravenous agent during renal imaging. To be

Ultrasound contrast developer Andaris is exploring radiological applications for its Quantison agent. The Nottingham, U.K.-based company has begun a phase II clinical trial to examine the efficiency of the intravenous agent during renal imaging. To be conducted at the University Hospital Dijkzigt in Rotterdam, the Netherlands, the trial will employ Quantison during renal imaging in patients with hypertension resulting from renal artery stenosis that was proven angiographically.

Quantison, which consists of a 3-micron air-filled albumin microcapsule, was initially designed for myocardial perfusion and cardiac chamber analysis; previous clinical studies have showed good results in both left ventricular opacification and myocardial perfusion, according to the company. In February, company executives said that Quantison might also be suitable for peripheral vascular and general radiology applications (SCAN 2/5/97).

Related Videos
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.